KALOFONOS ISABEL (Chief Commercial Officer) sold 75.0% of their position (2.50K shares) of CRINETICS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $137.5K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/7/2026ACC: 0001628280-26-001230
Officer· Chief Commercial Officer
Since Feb 2026
-2.50K
Net shares
Net seller
$137.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
2.50K acquired · 5K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+2.50K
Price / share
$40.59
Trade value
$101.48K
% of position
299.8%
1/5/2026
834.00→3.33K
Common Stock
Direct
Shares
−2.50K
Price / share
$55.00
Trade value
$137.50K
% of position
75.0%
1/5/2026
3.33K→834.00
Total
Net shares
+0.00
Net value
-$36.02K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/5/2026 | M · Option Exercise | +2.50K | $40.59 | $101.48K | 299.8% | 834.00 | 3.33K |
| Common Stock Direct | 1/5/2026 | S · Sale | −2.50K | $55.00 | $137.50K | 75.0% | 3.33K | 834.00 |
| Total | +0.00 | -$36.02K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
2.50K shares
Shares
−2.50K
Strike price
40.59
Held after
97.50K
Exercisable
—
1/5/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock2.50K shares | 1/5/2026 | M · Option Exercise | −2.50K | 40.59 | — | 97.50K |